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from 51 to 1783 ml. HDR brachytherapy was performed in 
order to reduce tumor volume and to decrease invasive 
potential of MSTS during non-compartmental surgery. After 
SPECT-CT preplanning, CT guided insertion of plastic needles 
and final HDR therapy planning 3 fractions of 7 Gy (with at 
least 5-6 hours of interfractional interval) were delivered in 
first 4 patients and 3 fractions of 8Gy – in last 5 cases.  
SPECT-CT with 99mTc-MIBI was performed before treatment 
in order to visualize viable tumour subregions and every 3-4 
weeks after brachytherapy for monitoring its efficacy and in 
order to determine optimal time for surgical intervention 
Results: In 6 of 7 patients with MSTS of extremities HDR 
brachytherapy converted treatment strategy from 
amputation to limb preserving surgery. In 2 of these 6 
patients amputations were performed 3-6 months after 
primary treatment. One of 2 patients with pelvic MSTS was 
considered operable 3 months after HDR brachytherapy. 
Postoperative consolidation external beam radiotherapy 
(45Gy) was performed in this case without early and late 
complications. 
SPECT-CT with 99mTc-MIBI effectively visualized viable and 
hypoxic-necrotic subregions of MSTS. After treatment SPECT-
CT correctly determine tumour regression in all 2 patients 
with pathomorphological complete or nearly complete (>90%) 
response, all 2 cases with partial pathologic response and 3 
observations of stabilization or tumour progression. All 4 
patients with complete or partial SPECT-CT response 
underwent limb saving surgery and are in remission. 
Conclusions: In patients with recurrent MSTS HDR interstitial 
brachytherapy can increase frequency of limb saving 
operations and converted inoperable tumours to operable. 
99mTc SPECT-CT can accurately determine response of MSTS 
to HDR brachytherapy and can be used for monitoring of 
treatment efficacy. 
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Purpose/Objective: To evaluate the treatment benefit of 
using custom mold surface applicators, computer-optimized 
high dose rate brachytherapy for cutaneous lymphoma. 
Materials and Methods: Seven patients with T cell lymphoma 
and one patient with anaplastic large cell lymphoma were 
treated at our department. A total of 41 sites where treated, 
two of which were retreat. The skin areas to be treated were 
delineated with radiopaque wires. Individual complex custom 
molds were created using Aquaplast thermoplastic base 
(QfixTM) and Freiburg catheters. A CT scan was performed 
with radio-opaque dummy markers placed inside the 
catheters, in order to conduct accurate 3D treatment 
planning. The data was then transferred to the brachytherapy 
planning system. A dose of 800cGy in 2 fractions was used for 
palliation. Higher doses like 2000cGy in 8 fractions were used 
for more extensive disease or re-treatment and up to 
4000cGy in 20 fractions with the goal of long term response. 
A computerized treatment volume was created that had a 
dimension identical to the skin area defined by the 
radiopaque wires and a thickness equal to the prescription 
depth of 3 mm. 
Results: The median follow up was 17.9 months (range 1.6 to 
43.3 months). Seven of the eight patients reported complete 
resolution of pain for a total of 39 treated sites. One patient 
recurred in both sites treated with HDR and also in sites 
treated with electron beam therapy. She was re-treated with 
a higher dose, her recent biopsies shows mycosis fungoides.  
 
 
The RTOG skin morbidity scale was used to assess the 
cosmetic outcome. For all sites treated with 800cGy no grade 
1-4 toxicity was noted. In one site treated with 3000cGy a 
grade 1 late reaction in the form of a very discreet skin 
tanning and dryness was seen. The two re-treated sites had a 
late RTOG scale of 2: some patch atrophy, pigmentation 
changes, very dry flaky skin. 
 
 
 
Conclusions: Skin lymphomas can be very aggressive and 
debilitating if not treated. Fortunately they have a very good 
response to radiation treatments. For complex geometries, 
including curved and large surfaces, HDR brachytherapy 
techniques using custom molds will provide better coverage 
when compared to external beam or electron therapy. This 
technique provides excellent dose conformity, while 
delivering a lesser dose to adjacent normal organs. The 
clinical outcome was excellent with most patients describing 
resolution of pain and good cosmetic outcome. 
 
 
Poster: Brachytherapy track: Intraoperative radiation 
therapy (IORT)  
